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InductionofdiﬀerentiationandapoptosisincancercellsbyligandsofPPARγ isanoveltherapeuticapproachtomalignanttumors.
Chondrosarcoma (malignant cartilage tumor) and OUMS-27 cells (cell line established from grade III human chondrosarcoma)
express PPARγ.P P A R γ ligands inhibited cell proliferation in a dose-dependent manner, and induced apoptosis of OUMS-27. The
higher-grade chondrosarcoma expressed a higher amount of antiapoptotic Bcl-xL in vivo. The treatment of OUMS-27 by 15d-
PGJ2, the most potent endogenous ligand for PPARγ, downregulated expression of Bcl-xL and induced transient upregulation
of proapoptotic Bax, which could accelerate cytochrome c release from mitochondria to the cytosol, followed by induction of
caspase-dependent apoptosis. 15d-PGJ2 induced the expression of CDK inhibitor p21 protein in human chondrosarcoma cells,
which appears to be involved in the mechanism of inhibition of cell proliferation. These ﬁndings suggest that targeted therapy
with PPARγ ligands could be a novel strategy against chondrosarcoma.
Copyright © 2008 K. Nishida et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Cancers are associated with dysregulation of diﬀerentia-
tion and apoptotic cell death. Recent investigations have
demonstrated that induction of these cellular events by
targeted therapy with ligands of nuclear hormone receptors
could be a novel strategy against cancers [1]. Peroxisome
proliferator-activated receptor (PPAR)γ, a member of the
nuclear receptor superfamily, acts as a ligand-activated tran-
scription factor, and is involved in many processes important
for homeostasis of cells and tissues, including metabolism,
immune and inﬂammatory controls, cell proliferation and
apoptotic cell death [2–6]. Because PPARγ is expressed
by many malignant tumors, activation of PPARγ by 15-
deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), the most potent
endogenous ligand for PPARγ [7], and the synthetic PPARγ
ligands (e.g., rosiglitazone, pioglitazone, troglitazone, and
indomethacin) have been regarded as a novel therapeutic
approach for certain human malignancies through growth
inhibition, induction of apoptosis and terminal diﬀerenti-
ation, and inhibition of angiogenesis [8]. This review will
outline the inhibitory eﬀects of synthetic and endogenous
PPARγ ligands and discuss their potential therapeutic eﬀects
on chondrosarcoma.
2. CLINICAL FEATURES OF CHONDROSARCOMA
Chondrosarcoma is a malignant tumor of cartilage; the
matrixformedbytumorcellsisuniformlyandentirelychon-
d r o i di nn a t u r e[ 9]. Human chondrosarcoma is a rare bone
tumor, accounting for <10% of primary malignant bone
tumors. Chondrosarcoma also arises in pre-existing benign
lesions (e.g., osteochondromatosis, enchondromatosis) and
is termed “secondary chondrosarcoma.”
Primary (conventional) chondrosarcoma arises centrally
in a previously normal bone, and mostly grows slowly
through the diaphyseal cortex. Most patients are aged >50
years. Conventional chondrosarcoma is more common in
men. The commonest sites are the bones of the pelvis,
followed by the femur and the humerus. Recognizable
histologic variants are clear cell, mesenchymal, and ded-
iﬀerentiated chondrosarcomas. On the basis of histologic2 PPAR Research
features (nuclear atypia and cellularity), conventional chon-
drosarcoma is further subdivided into three grades: I, II, and
III [10]. The histologic grade of chondrosarcoma indicates
the diﬀerentiation status of tumor cells, and is one of
the most important factors for prognosis [11]. Progression
of a locally aggressive low-grade chondrosarcoma to a
metastasizing high-grade chondrosarcoma is associated with
loss of cartilaginous phenotype, genomic instability, and
aneuploidy [12]. The grading of chondrosarcoma correlates
well with clinical behavior, although chondrosarcoma is one
of the most diﬃcult malignant tumors of bone to diagnose
[13].
Most conventional chondrosarcomas are grade I or II.
For low-grade chondrosarcoma, surgical treatment with
adequate marginal resection is reported to be associated
with better clinical outcomes [14]. Only 5–10% of conven-
tional chondrosarcomas are grade-III lesions, which have
deﬁnite metastatic potential. The prognosis for high-grade
chondrosarcoma is poor, despite adequate surgery, because
they are highly resistant to conventional chemotherapy and
radiotherapy [15]. These facts, that the diﬀerentiation status
ofchondrosarcomaispredictiveofclinicaloutcomes,suggest
the favorableeﬀectsof the modiﬁcation of the diﬀerentiation
statusonclinicalbehavior.Recentadvancesinunderstanding
the progression or development of chondrosarcoma have
suggested several molecular targets for future development
of new adjuvant therapy [16], such as chondrocyte diﬀeren-
tiation factors (PTHrP, CTGF) [17, 18], antiapoptotic gene
(Bcl-2)[ 19, 20], tumor suppressor gene (p16, p53)[ 21, 22],
and others (PDGF-α,V E G F ,MDR-1)[ 23–25].
3. OUMS-27, A CHONDROSARCOMA CELL LINE
A cell line derived from chondrosarcoma, particularly from
high-grade chondrosarcoma, can provide a useful model
for the investigation of cell development and treatment of
chondrosarcoma [26–30]. The OUMS-27 cell line has been
established from grade III human chondrosarcoma [31].
The cells do not show contact inhibition after reaching
conﬂuence, grow rapidly in multiple layers, and express
proteoglycan, as well as collagen type I, II, III, IX, and
XI after 120 passages, showing stable maintenance of the
diﬀerentiated chondrocytic properties. The transplantation
of OUMS-27 cells into athymic mice resulted in formation
of grade II chondrosarcoma at the injection site. There
have been many studies on the etiology and treatment of
chondrosarcoma using this cell line [32–34].
4. EXPRESSION OF PPARγ IN HUMAN
CHONDROSARCOMA AND OUMS-27
Subramanian et al. [35] investigated gene expression proﬁl-
ing of ten extraskeletal myxoid chondrosarcomas (EMCs)
using 42000 spot cDNA microarrays. Eighty-six genes that
distinguished EMC from the other sarcomas were identiﬁed
by signiﬁcance analysis of microarrays with 0.25% likelihood
of false signiﬁcance. Of these, PPARG and PPARGC1A, an
interacting protein with PPARG and also a coactivator, were
highly expressed in EMCs.
Table 1: Summary of immunohistochemical study for PPARγ in
human chondrosarcoma tissues.
Positive cell Pathological grade of chondrosarcoma (%)
ratios (%) I (n = 20) II (n = 6) III (n = 2)
<10 35 17 50
10–40 40 33 50
>40 25 50 0
In vivo PPARγ protein content was examined in conven-
tional chondrosarcoma specimens from 28 patients under-
going surgery [36]. Immunohistochemical study revealed
that human chondrosarcoma cells frequently express PPARγ
protein. The positivity (cutoﬀ p o s i t i v i t yo f1 0 % )o fc h o n -
drosarcoma cells were 65.0% in grade I, 83.3% in grade II,
and 50.0% in grade III; overall positivity was 67.9% (see
Table 1). Expression of PPARγ in OUMS-27 cells at protein
and mRNA levels was conﬁrmed by immunocytochemistry
and reverse transcriptase-polymerase chain reaction (RT-
PCR) analysis, respectively [36]. These data indicated that
PPARγ is frequently expressed in primary chondrosarcomas
and chondrosarcoma cell line OUMS-27, and led the authors
to test the eﬀectof PPARγ activators on cell proliferation and
survival of OUMS-27.
5. EVIDENCE OF APOPTOTIC CELL DEATH
OF OUMS-27 CELLS AFTER TREATMENT BY
PPARγ LIGANDS
In our previous report [36], OUMS-27 cells were treated
with increasing concentrations of pioglitazone (synthetic
PPARγ ligand) and 15d-PGJ2 for up to 48 hours. The
results of immunostain for Ki-67 (cell proliferation marker)
and colorimetric MTT assay showed that treatment with
both pioglitazone and 15d-PGJ2 for 24 hours inhibited
cell growth and reduced cell viability in a dose-dependent
manner, respectively. 15d-PGJ2 h a dm o r en o t i c e a b l ee ﬀects
on OUMS-27 cell growth than pioglitazone. It was unclear
whether the eﬀects of ligands on OUMS-27 cells were strictly
due to PPARγ activation. When cells were treated with 15d-
PGJ2 dosesof ≥5μg/mL,theyshowedrelativelyroundshapes
and some cells no longer adhered to the dish.
Semithin sectioned, LR White-embedded cells stained by
toluidine blue revealed that many OUMS-27 cells treated
with 15d-PGJ2 show apoptotic appearances with cell shrink-
age and nuclear condensation (see Figure 1). DNA fragmen-
tations in OUMS-27 cells treated by 15d-PGJ2 (10μg/mL)
f o r2 4h o u r sw e r ec o n ﬁ r m e db yD N Al a d d e rf o r m a t i o n
and TUNEL staining. Transmission electron microscopic
study revealed sections of OUMS-27 cells treated with 15d-
PGJ2 contained many cells consistent with morphological
apoptosis with condensed chromatin, many vacuoles in
cytoplasm, and membrane budding. Early apoptotic change
and the translocation of phosphatidylserine (PS) on the
outer leaﬂet of the cell membrane were demonstrated by
FACS analysis. The population of apoptotic cells with PS
at the outer membrane of the cells (annexin-V-positive,K. Nishida et al. 3
(a)
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Figure 1: Cell morphology of chondrosarcoma cell line OUMS-
27 after incubation with (b) or without (a) 15d-PGJ2.C e l l sw e r e
treated with 10μg/mL of 15d-PGJ2 for 8 hours, and the cell
pellet embedded in hydrophilic resin. Semithin sections stained by
toluidine blue show more apoptotic cells with cell shrinkage and
nuclear condensation (arrows) after treatment with 15d-PGJ2.
PI-negative) was ∼53.9% and 67.6% at 4 hours and 24 hours
after coincubation with 15d-PGJ2,r e s p e c t i v e l y .
6. MECHANISM OF APOPTOTIC CELL DEATH OF
OUMS-27 CELLS BY PPARγ LIGANDS
cDNA microarray analysis was carried out to comprehen-
sively explore the changes in gene expression pattern during
OUMS-27cellgrowthinhibitionandpossiblecellcyclearrest
caused by treatment with 15d-PGJ2 [37]. Among the 1081
genes analyzed, 52 genes were upregulated and 81 genes were
downregulated signiﬁcantly in OUMS-27 cells after 8-hour
treatment with 15d-PGJ2 (10μg/mL). Microarray analysis
is shown in Table 2. Interestingly, the proapoptotic gene
Bax was upregulated, and the antiapoptotic gene Bcl-xL was
downregulated. The other Bcl-2 members were unchanged.
These results were further conﬁrmed by RT-PCR and real-
time PCR analysis.
Upregulation of Bax, concurrent with the downregu-
lation of Bcl-xL, can destabilize mitochondria, leading to
the release of several mitochondrial intermembrane space
proteins such as cytochrome c, AIF, Smac/DIABLO, Endo
G, and Omi/HtrA2 into the cytosol, where they are actively
involved in apoptotic cell death [38]. This hypothesis is
supported by our observations of the release of cytochrome
c from mitochondria into the cytosol, and the activation of
caspase-3in15d-PGJ2-treatedOUMS-27cells.Coincubation
Table 2: Changes in apoptosis-related gene expression in OUMS-
27 cells after treatment with 15d-PGJ2.
Gene name Fold
Clusterin +3.7
Defender against cell death 1 +3.8
T u m o rn e c r o s i sf a c t o rr e c e p t o r1 + 3 . 2
State-induced state inhibitor 2 +2.5
Heat shock protein 60 +2.4
V-akt murine thymoma viral oncogene homolog 1 +2.3
Apoptosis regulator bax +2.3
Interferon-induced RNA-dependent protein kinase +2.1
Apoptosis regulator bcl-xl −2.2
Calpain, small subunit 1 −2.3
Heat shock 70 KD protein 1 −2.4
Endothelin 2 −2.4
Insulin-like growth factor 1 receptor −2.5
Death-associated protein 6 −2.8
of cells with the broad-spectrum caspase inhibitor Z-VAD-
FMK completely inhibited caspase activity, and prevented
the cell death induced by 15d-PGJ2. These results indicate
that 15d-PGJ2 induced apoptosis in OUMS-27 cells through
a caspase-dependent signal transduction pathway which, at
least in part, was triggered by cytosolic release of cytochrome
c[ 37].
The decreased expression of antiapoptotic Bcl-xL in
OUMS-27 treated by 15d-PGJ2 led us to examine the
expression in the tissue of human chondrosarcoma samples
to study the clinical application of diﬀerentiation therapy by
PPARγ activation. The result of immunohistochemical study
demonstrated that Bcl-xL was expressed in all three grades of
chondrosarcoma; the expression was strongest in grade III.
These results indicated that higher-grade chondrosarcoma
cells may be resistant to apoptosis by overexpression of Bcl-
xL, and 15d-PGJ2 might induce apoptotic cell death by
downregulation of Bcl-xL and transient upregulation of Bax
[37]. Similar results were reported in renal cell carcinoma
cells (786-O and A498 cells) showing the thiazolidinedione
(TZD) induction of apoptosis with increased Bax expression
and decreased Bcl-2 expression [39].
6.1. Geneticandepigeneticalterationsin
chondrosarcoma
Little is known about the role of genetic or epigenetic
alterations in tumor progression from low-malignant chon-
droblastic to highly malignant anaplastic chondrosarcoma.
T h ea p p e a r a n c eo fd en o v oa b e r r a n tD N Am e t h y l a t i o ni s
the commonest molecular change in the cancer cell, which
inactivates many cellular pathways [40]. The most studied
change of DNA methylation in neoplasms is the silencing
of tumor suppressor genes by deoxy-cytidylatephosphate-
deoxy-guanylate (CpG) island promoter hypermethylation,
which targets genes and molecules associated in cell dif-
f e r e n t i a t i o n ,s u c ha sp 1 6 ( I N K 4 a ) ,B R C A 1 ,a n dh M L H 14 PPAR Research
[41–43]. R¨ opke et al. reported the p16 and E-cadherin
promotermethylationinlow-gradechondroidcompartment
of dediﬀerentiated chondrosarcoma. Van Beerendonk et al.
found p16 promoter methylation by methylation-speciﬁc
PCR in 5 of 30 tumors, but this did not correlate with
protein expression, or with loss of heterozygosity (LOH) at
9p21 region, one of the few consistent genetic aberrations
found in conventional chondrosarcoma [44]. In OUMS-27,
methylation was not detectable in the promoter of p16 gene
(unpublished data).
Some reports suggested that p53 mutation and p53 loss
ofheterozygosityareinvolved[43,45].InOUMS-27,wehave
previously shown that the p53 gene is mutated [31]. Asp
et al.analyzedp16andp53incartilaginoustumortissuesand
showed that the p16 gene was found to be partly methylated
in5high-gradechondrosarcomasandhomozygouslydeleted
in 1 chondrosarcoma, whereas the p53 gene revealed an
unchanged structure in all 22 chondrosarcoma samples [46].
7. INDUCTION OF CELL CYCLE ARREST BY
15d-PGJ2 IN OUMS-27
Ligands for PPARγ reportedly induce cell cycle arrest in vari-
ous cancer cells [39, 47–54]. 15d-PGJ2 induces G1 arrest and
inhibits cell growth of human anaplastic thyroid carcinoma
through a p53-independent, but p21- and p27-dependent,
manner [55]. Activation of PPARγ by troglitazone inhibited
cell growth and induced G1 arrest through the increase of
cycline-dependent kinase (CDK) inhibitor p27 in several cell
lines, including human pancreatic carcinoma cells, gastric
cancer cells, and hepatocellular carcinoma cells [56–58]. The
eﬀect of troglitazone on the proliferation of cancer cells
was inhibited by antisense for p27. Yang et al. also showed
TZD decreased the protein levels of proliferating cell nuclear
antigen, pRb, cyclin D, and Cdk4, but increased the levels of
p21 and p27, in RCC cells [39].
In OUMS-27, 15d-PGJ2 induced the expression of the
CDK inhibitor p21 protein, and it was increased within 24
hours. Expression of the other CDK inhibitors, p16 and
p27 proteins, were detected at time zero, and were not
signiﬁcantly inﬂuenced by 15d-PGJ2 treatment [37]. 15d-
PGJ2-induced p21 may exert cell cycle arrest in a p53-
independent manner.
Whether 15d-PGJ2 induces p21 expression in OUMS-27
cells through a PPARγ-dependent or -independent pathway
is unclear. It is possible that p21 expression is directly
regulated by PPARγ activation because p21 gene contains
a potentially conserved consensus PPARγ response element
in the promoter region [59]. Copland et al. reported [60]
that RS5444, a novel high-aﬃnity PPARγ agonist, inhibits
anaplastic thyroid cartinoma (ATC) tumor growth and
angiogenesis in mice. In DRO cells derived from ATC tumor,
they demonstrated that upregulation of p21 by RS5444 is
PPARγ dependent, and might be the major mechanism
by which RS5444 inhibits DRO cell proliferation. Han
et al. demonstrated the link of PPARγ activation and p21
signaling to cell growth inhibition in human lung cell
cartinoma cells using p21 antisense oligonucleotides [61].
They also indicated the induction of p21 expression by
PPARγ ligands might be mediated through increased Sp-1
and NF-interleukin 6 (IL6) CAAT/enhancer binding protein
(C/EBP)-dependent transcriptional activation.
8. CLINICAL APPLICATION OF PPARγ AGONIST FOR
CHONDROSARCOMA SUPPRESSION
AccumulatingevidencesuggeststhatPPARγ activatorsmight
have clinical therapeutic beneﬁt in the treatment of cancers.
Although initial clinical trials with troglitazone reported
promising results in liposarcomas [62] and prostate cancers
[63], recent studies failed to show the expected therapeutic
values of rosiglitazone in liposarcomas [64]a n de a r l y -
stage breast cancers [65], and troglitazone in chemotherapy-
resistantmetastatic colorectalcancers[66].However, asingle
study of a phase-I clinical trial of LY293111 in patients with
advancedsolidtumorsreportedapotentialeﬃcacyofPPARγ
agonist for chondrosarcoma [67]. LY293111 is an orally
stable leukotriene B4 (LTB4) receptor antagonist, as well as a
PPARγ agonist, as demonstrated by activity in the rat ZDF
diabetes model, and the induction of adipocyte diﬀeren-
tiation. One patient with progressive chondrosarcoma had
stable disease lasting ∼336 days of LY293111 administration
at the dose of 200mg bd.
9. FUTURE DIRECTION
In chondrosarcoma, whether the cell death and growth
inhibitory eﬀects induced by 15d-PGJ2 are PPARγ-depend-
ent or -independent is unknown. As 15d-PGJ2 at high
doses is toxic for most of cell types independent of
PPARγ activation, we examined the eﬀects of the caspase
inhibitor Z-VAD-FMK, and the PPARγ antagonist GW9662,
on caspase-3 activation and cell viability of OUMS-27
cells treated by 15d-PGJ2 [37]. 15d-PGJ2 alone clearly
increased cell death; the addition of GW9662 partially
inhibited cell death. Cell death was inhibited almost to
control level when Z-VAD-FMK was added to 15d-PGJ2.
The activity of caspase-3 was attenuated, though not com-
pletely, by stimulation of 15d-PGJ2 together with GW9662.
These data indicate that the greater proapoptotic eﬀects
of 15d-PGJ2 on chondrosarcoma cells may result from the
cumulative eﬀects of PPARγ-dependent and -independent
pathways. Detailed analysis of the eﬀects of ligands on
cells transfected with PPARγ siRNA should provide impor-
tant clues to understanding this phenomenon. Whether
endogenous or synthetic PPARγ ligands can also induce
tumor cell death in an experimentally transplanted chon-
drosarcoma model remains to be examined before human
trial.
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